Compare Stocks

Date Range: 

 Knight TherapeuticsHLS TherapeuticsHEXOZomedicaOrganiGram
SymbolTSE:GUDTSE:HLSTSE:HEXONYSEAMERICAN:ZOMTSE:OGI
Price Information
Current PriceC$5.32C$18.57C$8.93$0.85C$3.35
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.71.40.70.91.2
Analysis Score3.53.71.31.52.9
Community Score3.13.12.12.91.9
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score1.90.00.00.01.3
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price TargetC$7.88C$30.50C$1.79$0.30C$3.78
% Upside from Price Target48.03% upside64.24% upside-79.97% downside-64.59% downside12.75% upside
Trade Information
Market CapC$685.02 millionC$590.94 millionC$1.09 billion$477.81 millionC$999.08 million
BetaN/AN/AN/AN/AN/A
Average Volume364,39435,5812,243,042144,502,4224,300,335
Sales & Book Value
Annual RevenueC$199.52 millionC$56.11 millionC$111.62 millionN/AC$72.40 million
Price / Sales3.4310.539.79N/A13.80
CashflowC$3.13 per shareC$0.63 per shareC$1.14 per shareN/AC$0.25 per share
Price / Cash1.7029.327.86N/A13.19
Book ValueC$6.82 per shareC$5.32 per shareC$4.42 per shareN/AC$1.14 per share
Price / Book0.783.492.02N/A2.94
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSC$0.32C($0.60)C($2.02)N/AC($1.14)
Trailing P/E Ratio16.68N/AN/A0.00N/A
Forward P/E Ratio
P/E GrowthN/AN/AN/AN/A0.09
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AC$0.15N/AN/AN/A
Dividend YieldN/A0.80%N/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/A N/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio6.34%66.02%16.03%N/A23.71%
Current Ratio4.84%1.29%4.30%N/A6.66%
Quick Ratio4.23%0.93%2.37%N/A4.11%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees6798837419619
Shares Outstanding128.76 million31.82 million122.39 million564.05 million298.23 million
Next Earnings Date6/25/2021 (Estimated)8/5/2021 (Estimated)6/9/2021 (Estimated)5/10/2021 (Estimated)7/20/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableOptionable
SourceHeadline
OrganiGram Holdings Inc. (NASDAQ:OGI) Crashes 0% In 2021; Is It Attractive Enough At $2.5?OrganiGram Holdings Inc. (NASDAQ:OGI) Crashes 0% In 2021; Is It Attractive Enough At $2.5?
marketingsentinel.com - May 7 at 4:15 AM
FY2022 Earnings Forecast for OrganiGram Holdings Inc. (TSE:OGI) Issued By Cantor FitzgeraldFY2022 Earnings Forecast for OrganiGram Holdings Inc. (TSE:OGI) Issued By Cantor Fitzgerald
americanbankingnews.com - May 6 at 10:04 AM
OrganiGram (TSE:OGI) Given "Outperform" Rating at Raymond JamesOrganiGram (TSE:OGI) Given "Outperform" Rating at Raymond James
americanbankingnews.com - May 4 at 3:04 PM
Sundial vs. OrganiGram: Which Cannabis Stock Is a Better Buy? By StockNews - Investing.comSundial vs. OrganiGram: Which Cannabis Stock Is a Better Buy? By StockNews - Investing.com
investing.com - May 4 at 1:32 PM
OrganiGram CEO: This 1 Big Change Could Shake Up the Canadian Cannabis Market This Year - Motley FoolOrganiGram CEO: This 1 Big Change Could Shake Up the Canadian Cannabis Market This Year - Motley Fool
fool.com - May 4 at 8:32 AM
Organigram CEO Engel exits struggling marijuana producer - Marijuana Business DailyOrganigram CEO Engel exits struggling marijuana producer - Marijuana Business Daily
mjbizdaily.com - May 4 at 8:32 AM
OrganiGram CEO: This 1 Big Change Could Shake Up the Canadian Cannabis Market This YearOrganiGram CEO: This 1 Big Change Could Shake Up the Canadian Cannabis Market This Year
finance.yahoo.com - May 4 at 8:32 AM
Canadian cannabis company Organigram says CEO Greg Engel is stepping down with immediate effect - MarketWatchCanadian cannabis company Organigram says CEO Greg Engel is stepping down with immediate effect - MarketWatch
marketwatch.com - May 4 at 12:22 AM
OrganiGram Holdings Inc. (NASDAQ:OGI) – Does It Provide Stability And Growth?OrganiGram Holdings Inc. (NASDAQ:OGI) – Does It Provide Stability And Growth?
stocksregister.com - May 2 at 8:30 AM
OrganiGram Holdings (OGI) Stock Comes back Strongly: Should You Get In Now? – Own Snap - Own SnapOrganiGram Holdings (OGI) Stock Comes back Strongly: Should You Get In Now? – Own Snap - Own Snap
ownsnap.com - April 29 at 10:12 AM
OrganiGram: The Hype Is Over - Seeking AlphaOrganiGram: The Hype Is Over - Seeking Alpha
seekingalpha.com - April 27 at 7:41 PM
OrganiGram Holdings Inc. (NASDAQ:OGI) Stock Forecast: Upsidde of 10.74% by 2021OrganiGram Holdings Inc. (NASDAQ:OGI) Stock Forecast: Upsidde of 10.74% by 2021
stocksregister.com - April 27 at 9:40 AM
Q3 2021 EPS Estimates for OrganiGram Holdings Inc. (TSE:OGI) Cut by Jefferies Financial GroupQ3 2021 EPS Estimates for OrganiGram Holdings Inc. (TSE:OGI) Cut by Jefferies Financial Group
americanbankingnews.com - April 26 at 2:14 AM
Q4 2021 Earnings Estimate for OrganiGram Holdings Inc. Issued By Jefferies Financial Group (TSE:OGI)Q4 2021 Earnings Estimate for OrganiGram Holdings Inc. Issued By Jefferies Financial Group (TSE:OGI)
americanbankingnews.com - April 23 at 8:34 AM
Organigram Expands Edison Cannabis Co. Dried Flower Portfolio with Two New High THC Strains: GMO Cookies and MAC-1 - Argus PressOrganigram Expands Edison Cannabis Co. Dried Flower Portfolio with Two New High THC Strains: GMO Cookies and MAC-1 - Argus Press
argus-press.com - April 22 at 7:19 PM
Organigram Expands Edison Cannabis Co. Dried Flower Portfolio with Two New High THC Strains: GMO Cookies and MAC-1 - Yahoo FinanceOrganigram Expands Edison Cannabis Co. Dried Flower Portfolio with Two New High THC Strains: GMO Cookies and MAC-1 - Yahoo Finance
finance.yahoo.com - April 22 at 6:40 PM
Jefferies Financial Group Boosts OrganiGram (TSE:OGI) Price Target to C$3.57Jefferies Financial Group Boosts OrganiGram (TSE:OGI) Price Target to C$3.57
americanbankingnews.com - April 22 at 2:57 PM
Organigram Expands Edison Cannabis Co. Dried Flower Portfolio with Two New High THC Strains: GMO Cookies and MAC-1 - ManchestertimesOrganigram Expands Edison Cannabis Co. Dried Flower Portfolio with Two New High THC Strains: GMO Cookies and MAC-1 - Manchestertimes
manchestertimes.com - April 22 at 2:18 PM
Organigram Expands Edison Cannabis Co. Dried Flower Portfolio with Two New High THC Strains: GMO Cookies and MAC-1 - StreetInsider.comOrganigram Expands Edison Cannabis Co. Dried Flower Portfolio with Two New High THC Strains: GMO Cookies and MAC-1 - StreetInsider.com
streetinsider.com - April 22 at 1:36 PM
Organigram Expands Edison Cannabis Co. Dried Flower Portfolio with Two New High THC Strains: GMO Cookies and MAC-1Organigram Expands Edison Cannabis Co. Dried Flower Portfolio with Two New High THC Strains: GMO Cookies and MAC-1
finance.yahoo.com - April 22 at 1:36 PM
OrganiGram Holdings (OGI) Q2 2021 Earnings Call Transcript - Motley FoolOrganiGram Holdings (OGI) Q2 2021 Earnings Call Transcript - Motley Fool
fool.com - April 22 at 12:43 AM
OrganiGram Holdings (OGI) Q2 2021 Earnings Call TranscriptOrganiGram Holdings (OGI) Q2 2021 Earnings Call Transcript
finance.yahoo.com - April 22 at 12:43 AM
Bear of the Day: OrganiGram Holdings (OGI)Bear of the Day: OrganiGram Holdings (OGI)
finance.yahoo.com - April 21 at 9:08 AM
Levi Strauss, OrganiGram Holdings, United Natural Foods, Sprouts Farmers Market and Performance Food Group highlighted as Zacks Bull and Bear of the DayLevi Strauss, OrganiGram Holdings, United Natural Foods, Sprouts Farmers Market and Performance Food Group highlighted as Zacks Bull and Bear of the Day
finance.yahoo.com - April 21 at 9:08 AM
OrganiGram Holdings Inc. (TSE:OGI) Receives Consensus Rating of "Hold" from BrokeragesOrganiGram Holdings Inc. (TSE:OGI) Receives Consensus Rating of "Hold" from Brokerages
americanbankingnews.com - April 21 at 2:44 AM
DateCompanyBrokerageAction
4/26/2021Knight TherapeuticsNational Bank FinancialBoost Price Target
4/26/2021Knight TherapeuticsNational BanksharesBoost Price Target
4/26/2021Knight TherapeuticsRaymond JamesBoost Price Target
3/26/2021Knight TherapeuticsBloom BurtonUpgrade
11/16/2020Knight TherapeuticsRoyal Bank of CanadaLower Price Target
4/1/2020Knight TherapeuticsCanaccord GenuityLower Price Target
1/2/2020HLS TherapeuticsClarus SecuritiesReiterated Rating
3/19/2021HEXOMKM PartnersBoost Price Target
12/16/2020HEXOStifel NicolausUpgrade
12/15/2020HEXOATB CapitalUpgrade
11/2/2020HEXOCormarkLower Price Target
11/2/2020HEXOStandpoint ResearchLower Price Target
6/17/2020HEXOJefferies Financial GroupBoost Price Target
6/12/2020HEXOCIBCBoost Price Target
6/12/2020HEXOEight CapitalLower Price Target
4/15/2020HEXOAlliance Global PartnersLower Price Target
11/16/2020ZomedicaHC WainwrightLower Price Target
4/14/2021OrganiGramHaywood SecuritiesLower Price Target
(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.